Immunological surrogate endpoints to evaluate vaccine efficacy / 中华预防医学杂志
Chinese Journal of Preventive Medicine
; (12): 1110-1114, 2015.
Article
in Zh
| WPRIM
| ID: wpr-296624
Responsible library:
WPRO
ABSTRACT
An immunological surrogate endpoints is a vaccine-induced immune response (either humoral or cellular immune) that predicts protection against clinical endpoints (infection or disease), and can be used to evaluate vaccine efficacy in clinical vaccine trials. Compared with field efficacy trials observing clinical endpoints, immunological vaccine trials could reduce the sample size or shorten the duration of a trial, which promote the license and development of new candidate vaccines. For these reasons, establishing immunological surrogate endpoints is one of 14 Grand Challenges of Global Health of the National Institutes of Health (NIH) and the Bill and Melinda Gates Foundation. From two parts of definition and statistical methods for evaluation of surrogate endpoints, this review provides a more comprehensive description.
Full text:
1
Index:
WPRIM
Main subject:
Research Design
/
Vaccines
/
Biomarkers
/
Clinical Trials as Topic
/
Data Interpretation, Statistical
/
Treatment Outcome
/
Allergy and Immunology
Type of study:
Prognostic_studies
Limits:
Humans
Language:
Zh
Journal:
Chinese Journal of Preventive Medicine
Year:
2015
Type:
Article